|
1
|
WHO: Cancer today. https://gco.iarc.fr/today/homeJune 24–2019
|
|
2
|
Daher S, Massarwa M, Benson AA and Khoury
T: Current and future treatment of hepatocellular carcinoma: An
updated comprehensive review. J Clin Transl Hepatol. 6:69–78. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park SJ, Jang JY, Jeong SW, Cho YK, Lee
SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, et al: Usefulness of
AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing
hepatocellular carcinoma. Medicine (Baltimore). 96:e58112017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma SA, Kowgier M, Hansen BE, Brouwer
WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, et al:
Toronto HCC risk index: A validated scoring system to predict
10-year risk of HCC in patients with cirrhosis. J Hepatol. Aug
24–2017.(Epub ahead of print). doi: 10.1016/j.jhep.2017.07.033.
|
|
5
|
Shen J, He L, Li C, Wen T, Chen W, Lu C,
Yan L, Li B and Yang J: Nomograms to predict the individual
survival of patients with solitary hepatocellular carcinoma after
hepatectomy. Gut Liver. 11:684–692. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Visone V, Vettone A, Serpe M, Valenti A,
Perugino G, Rossi M and Ciaramella M: Chromatin structure and
dynamics in hot environments: Architectural proteins and DNA
topoisomerases of thermophilic archaea. Int J Mol Sci.
15:17162–17187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi IY, Chung IK and Muller MT:
Eukaryotic topoisomerase II cleavage is independent of duplex DNA
conformation. Biochim Biophys Acta. 1264:209–214. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Austin CA, Lee KC, Swan RL, Khazeem MM,
Manville CM, Cridland P, Treumann A, Porter A, Morris NJ and Cowell
IG: TOP2B: The first thirty years. Int J Mol Sci. 19:27652018.
View Article : Google Scholar
|
|
9
|
Bush NG, Evans-Roberts K and Maxwell A:
DNA topoisomerases. EcoSal Plus. 6:2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antoniou-Kourounioti M, Mimmack ML, Porter
ACG and Farr CJ: The impact of the C-terminal region on the
interaction of topoisomerase II alpha with mitotic chromatin. Int J
Mol Sci. 20:12382019. View Article : Google Scholar
|
|
11
|
Demoulin B, Hermant M, Castrogiovanni C,
Staudt C and Dumont P: Resveratrol induces DNA damage in colon
cancer cells by poisoning topoisomerase II and activates the ATM
kinase to trigger p53-dependent apoptosis. Toxicol In Vitro.
29:1156–1165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sudan S and Rupasinghe HPV:
Flavonoid-enriched apple fraction AF4 induces cell cycle arrest,
DNA topoisomerase II inhibition, and apoptosis in human liver
cancer HepG2 cells. Nutr Cancer. 66:1237–1246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kania EE, Carvajal-Moreno J, Hernandez VA,
English A, Papa JL, Shkolnikov N, Ozer HG, Yilmaz AS, Yalowich JC
and Elton TS: hsa-miR-9-3p and hsa-miR-9-5p as post-transcriptional
modulators of DNA topoisomerase IIα in human leukemia K562 cells
with acquired resistance to etoposide. Mol Pharmacol. 97:159–170.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kanagasabai R, Karmahapatra S, Kientz CA,
Yu Y, Hernandez VA, Kania EE, Yalowich JC and Elton TS: The novel
c-terminal truncated 90-kDa isoform of topoisomerase IIα (TOP2α/90)
is a determinant of etoposide resistance in K562 leukemia cells via
heterodimerization with the TOP2α/170 isoform. Mol Pharmacol.
93:515–525. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
D Arcy N and Gabrielli B: Topoisomerase II
inhibitors and poisons, and the influence of cell cycle
checkpoints. Curr Med Chem. 24:1504–1519. 2017.PubMed/NCBI
|
|
16
|
Wang JC: Cellular roles of DNA
topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol.
3:430–440. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jain CK, Roychoudhury S and Majumder HK:
Selective killing of G2 decatenation checkpoint defective colon
cancer cells by catalytic topoisomerase II inhibitor. Biochim
Biophys Acta. 1853:1195–1204. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng SP and Guo WL: Identifying key genes
of liver cancer by networking of multiple data sets. IEEE/ACM Trans
Comput Biol Bioinform. 16:792–800. 2019. View Article : Google Scholar
|
|
19
|
Yu Y, Ding S, Liang Y, Zheng Y, Li W, Yang
L, Zheng X and Jiang J: Expression of ERCC1, TYMS, TUBB3, RRM1 and
TOP2A in patients with esophageal squamous cell carcinoma: A
hierarchical clustering analysis. Exp Ther Med. 7:1578–1582. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xing C, Cai Z, Gong J, Zhou J, Xu J and
Guo F: Identification of potential biomarkers involved in gastric
cancer through integrated analysis of non-coding RNA associated
competing endogenous RNAs network. Clin Lab. 64:1661–1669. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu LM, Xiong DD, Lin P, Yang H, Dang YW
and Chen G: DNA topoisomerase 1 and 2A function as oncogenes in
liver cancer and may be direct targets of nitidine chloride. Int J
Oncol. 53:1897–1912. 2018.PubMed/NCBI
|
|
22
|
Eltohamy MI, Badawy OM, El kinaai N, Loay
I, Nassar HR, Allam RM and Ali Sakr M: Topoisomerase II α gene
alteration in triple negative breast cancer and its predictive role
for anthracycline-based chemotherapy (Egyptian NCI Patients). Asian
Pac J Cancer Prev. 19:3581–3589. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wittmann S, Wunder C, Zirn B, Furtwängler
R, Wegert J, Graf N and Gessler M: New prognostic markers revealed
by evaluation of genes correlated with clinical parameters in wilms
tumors. Genes Chromosomes Cancer. 47:386–395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu XL, Zheng WH, Fu ZX, Li ZP, Xie HX, Li
XX, Jiang LH, Wang Y, Zhu SM and Mao WM: Topo2A as a prognostic
biomarker for patients with resectable esophageal squamous cell
carcinomas. Med Oncol. 32:3962015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Resende MF, Vieira S, Chinen LT,
Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I,
Pagotty S, Pellionisz PA, et al: Prognostication of prostate cancer
based on TOP2A protein and gene assessment: TOP2A in prostate
cancer. J Transl Med. 11:362013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Şahin S, Gönül II, Çakır A, Seçkin S and
Uluoğlu O: Clinicopathological significance of the proliferation
markers Ki67, RacGAP1, and topoisomerase 2 alpha in breast cancer.
Int J Surg Pathol. 24:607–613. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pei YF, Yin XM and Liu XQ: TOP2A induces
malignant character of pancreatic cancer through activating
β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis.
1864:197–207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Labbe DP, Sweeney CJ, Brown M, Galbo P,
Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, et
al: TOP2A and EZH2 provide early detection of an aggressive
prostate cancer subgroup. Clin Cancer Res. 23:7072–7083. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Villman K, Sjöström J, Heikkilä R,
Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E and
Blomqvist C: TOP2A and HER2 gene amplification as predictors of
response to anthracycline treatment in breast cancer. Acta Oncol.
45:590–596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ito F, Furukawa N and Nakai T: Evaluation
of TOP2A as a predictive marker for endometrial cancer with
taxane-containing adjuvant chemotherapy. Int J Gynecol Cancer.
26:325–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roca E, Berruti A, Sbiera S, Rapa I, Oneda
E, Sperone P, Ronchi CL, Ferrari L, Grisanti S, Germano A, et al:
Topoisomerase 2α and thymidylate synthase expression in
adrenocortical cancer. Endocr Relat Cancer. 24:319–327. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cai HY, Zhu XH, Qian F, Shao B, Zhou Y,
Zhang Y and Chen Z: High expression of TOP2A gene predicted poor
prognosis of hepatocellular carcinoma after radical hepatectomy.
Transl Cancer Res. 9:983–992. 2020. View Article : Google Scholar
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
R Core Team (2014): R, . A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: http://www.R-project.org/
|
|
35
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ecklund A: beeswarm: The Bee Swarm Plot,
an Alternative to Stripchart. https://CRAN.R-project.org/package=beeswarm
|
|
37
|
Kulik L and El-Serag HB: Epidemiology and
management of hepatocellular carcinoma. Gastroenterology.
156:477–491 e471. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yau T, Hsu C, Kim TY, Choo SP, Kang YK,
Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, et al: Nivolumab in
advanced hepatocellular carcinoma: Sorafenib-experienced Asian
cohort analysis. J Hepatol. 71:543–552. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Di Bisceglie AM and Hoofnagle JH:
Elevations in serum alpha-fetoprotein levels in patients with
chronic hepatitis B. Cancer. 64:2117–2120. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Agopian VG, Harlander-Locke MP, Markovic
D, Zarrinpar A, Kaldas FM, Cheng EY, Yersiz H, Farmer DG, Hiatt JR
and Busuttil RW: Evaluation of patients with hepatocellular
carcinomas that do not produce α-fetoprotein. JAMA Surg. 152:55–64.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X and
Tu J: Current status and perspective biomarkers in AFP negative
HCC: Towards screening for and diagnosing hepatocellular carcinoma
at an earlier stage. Pathol Oncol Res. 26:599–603. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
European Association For The Study Of The
Liver; European Organisation For Research and Treatment Of Cancer,
. EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yan L, Xu F and Dai C: Overexpression of
COL24A1 in hepatocellular carcinoma predicts poor prognosis: A
study based on multiple databases, clinical samples and cell lines.
Onco Targets Ther. 13:2819–2832. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Luo YD, Yu HQ, Liu XY, Huang D, Dai HS,
Fang L, Zhang YJ, Lai JJ, Jiang Y, Shuai L, et al: Prognostic and
predicted significance of Ubqln2 in patients with hepatocellular
carcinoma. Cancer Med. 9:4083–4094. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen L, Liu D, Yi X, Qi L, Tian X, Sun B,
Dong Q, Han Z, Li Q, Song T, et al: The novel miR-1269b-regulated
protein SVEP1 induces hepatocellular carcinoma proliferation and
metastasis likely through the PI3K/Akt pathway. Cell Death Dis.
11:3202020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen J, Ding C, Chen Y, Hu W, Lu Y, Wu W,
Zhang Y, Yang B, Wu H, Peng C, et al: ACSL4 promotes hepatocellular
carcinoma progression via c-Myc stability mediated by
ERK/FBW7/c-Myc axis. Oncogenesis. 9:422020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao X, Chen Y, Mao Q, Jiang X, Jiang W,
Chen J, Xu W, Zhong L and Sun X: Overexpression of YTHDF1 is
associated with poor prognosis in patients with hepatocellular
carcinoma. Cancer Biomark. 21:859–868. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li F, Bai L, Li S, Chen Y, Xue X and Yu Z:
Construction and evaluation of a prognosis lncRNA model for
hepatocellular carcinoma. J Cell Biochem. Apr 29–2020.(Epub ahead
of print). doi: https://doi.org/10.1002/jcb.29608.
|
|
49
|
Kou F, Sun H, Wu L, Li B, Zhang B, Wang X
and Yang L: TOP2A promotes lung adenocarcinoma cells' malignant
progression and predicts poor prognosis in lung adenocarcinoma. J
Cancer. 11:2496–2508. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu T, Zhang H, Yi S, Gu L and Zhou M:
Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
Mol Oncol. 13:1047–1058. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zeng S, Liu A, Dai L, Yu X, Zhang Z, Xiong
Q, Yang J, Liu F, Xu J, Xue Y, et al: Prognostic value of TOP2A in
bladder urothelial carcinoma and potential molecular mechanisms.
BMC Cancer. 19:6042019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Badawy OM and Loay I: FISH analysis of
TOP2A and HER-2 aberrations in female breast carcinoma on archived
material: Egyptian NCI experience. Appl Immunohistochem Mol
Morphol. 27:216–222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang R, Xu J, Zhao J and Bai JH:
Proliferation and invasion of colon cancer cells are suppressed by
knockdown of TOP2A. J Cell Biochem. 119:7256–7263. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xiong Y, Yuan L, Chen L, Zhu Y, Zhang S,
Liu X, Xiao Y and Wang X: Identifying a novel biomarker TOP2A of
clear cell renal cell carcinoma (ccRCC) associated with smoking by
co-expression network analysis. J Cancer. 9:3912–3922. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nelson WG, Haffner MC and Yegnasubramanian
S: The structure of the nucleus in normal and neoplastic prostate
cells: Untangling the role of type 2 DNA topoisomerases. Am J Clin
Exp Urol. 6:107–113. 2018.PubMed/NCBI
|
|
56
|
Panvichian R, Tantiwetrueangdet A,
Angkathunyakul N and Leelaudomlipi S: TOP2A amplification and
overexpression in hepatocellular carcinoma tissues. Biomed Res Int.
2015:3816022015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ng IO, Na J, Lai EC, Fan ST and Ng M:
Ki-67 antigen expression in hepatocellular carcinoma using
monoclonal antibody MIB1. A comparison with proliferating cell
nuclear antigen. Am J Clin Pathol. 104:313–318. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu
C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5
promotes human colorectal cancer metastasis through activation of
the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer.
16:702017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Echevarria MI, Awasthi S, Cheng CH,
Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein
EA, Freedland SJ, et al: African American specific gene panel
predictive of poor prostate cancer outcome. J Urol. 202:247–255.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rocha-Singh KJ: Retrospective real-world
studies of paclitaxel and mortality: Defining the many faces of
bias. JACC Cardiovasc Interv. May 14–2020.(Epub ahead of print).
doi: 10.1016/j.jcin.2020.05.006. View Article : Google Scholar : PubMed/NCBI
|
